JP2015529236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529236A5 JP2015529236A5 JP2015532465A JP2015532465A JP2015529236A5 JP 2015529236 A5 JP2015529236 A5 JP 2015529236A5 JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015529236 A5 JP2015529236 A5 JP 2015529236A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- fragment
- region
- protein
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 51
- 102000018358 immunoglobulin Human genes 0.000 claims 51
- 239000012634 fragment Substances 0.000 claims 42
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 230000004048 modification Effects 0.000 claims 18
- 238000012986 modification Methods 0.000 claims 18
- 238000006467 substitution reaction Methods 0.000 claims 16
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 13
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000000833 heterodimer Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 229940072221 immunoglobulins Drugs 0.000 claims 10
- 101710120037 Toxin CcdB Proteins 0.000 claims 9
- 239000003153 chemical reaction reagent Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 101100504121 Mus musculus Ighg gene Proteins 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 101001055315 Homo sapiens Immunoglobulin heavy constant alpha 1 Proteins 0.000 claims 2
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 claims 2
- 101000961146 Homo sapiens Immunoglobulin heavy constant gamma 2 Proteins 0.000 claims 2
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 claims 2
- 102100026217 Immunoglobulin heavy constant alpha 1 Human genes 0.000 claims 2
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims 2
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 claims 2
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 101000961145 Homo sapiens Immunoglobulin heavy constant gamma 3 Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102100039348 Immunoglobulin heavy constant gamma 3 Human genes 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705278P | 2012-09-25 | 2012-09-25 | |
| US61/705,278 | 2012-09-25 | ||
| PCT/EP2013/069989 WO2014049003A1 (en) | 2012-09-25 | 2013-09-25 | Purification of hetero-dimeric immunoglobulins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020450A Division JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Division JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529236A JP2015529236A (ja) | 2015-10-05 |
| JP2015529236A5 true JP2015529236A5 (cg-RX-API-DMAC7.html) | 2016-11-10 |
Family
ID=49237223
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532465A Pending JP2015529236A (ja) | 2012-09-25 | 2013-09-25 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018020450A Pending JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Expired - Fee Related JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
| JP2020036853A Ceased JP2020105203A (ja) | 2012-09-25 | 2020-03-04 | ヘテロ二量体免疫グロブリンの精製 |
| JP2022092045A Pending JP2022116326A (ja) | 2012-09-25 | 2022-06-07 | ヘテロ二量体免疫グロブリンの精製 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020450A Pending JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Expired - Fee Related JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
| JP2020036853A Ceased JP2020105203A (ja) | 2012-09-25 | 2020-03-04 | ヘテロ二量体免疫グロブリンの精製 |
| JP2022092045A Pending JP2022116326A (ja) | 2012-09-25 | 2022-06-07 | ヘテロ二量体免疫グロブリンの精製 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150239991A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2900696A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2015529236A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150076172A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104968685A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013322710A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2886036A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1215950A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL237872B (cg-RX-API-DMAC7.html) |
| IN (1) | IN2015MN00139A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014049003A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| JP6091894B2 (ja) | 2009-09-16 | 2017-03-15 | ジェネンテック， インコーポレイテッド | コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用 |
| AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| WO2012116927A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| MX341921B (es) | 2011-02-28 | 2016-09-07 | Hoffmann La Roche | Proteinas de union a antigeno. |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| UA118029C2 (uk) | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| CA2922979A1 (en) * | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
| EP3176185A1 (en) | 2013-11-04 | 2017-06-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| CN110981957B (zh) * | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| SG11201607983YA (en) | 2014-03-28 | 2016-10-28 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| WO2016016299A1 (en) * | 2014-07-29 | 2016-02-04 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| WO2017005649A1 (en) | 2015-07-09 | 2017-01-12 | Genmab A/S | Bispecific and multispecific antibodies and method for isolation of such |
| CN116789841A (zh) | 2015-10-25 | 2023-09-22 | 赛诺菲 | 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白 |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| HUE063824T2 (hu) | 2016-04-13 | 2024-02-28 | Sanofi Sa | Trispecifikus és/vagy trivalens kötõfehérjék |
| PE20190128A1 (es) | 2016-04-13 | 2019-01-17 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes |
| EP3889175A1 (en) * | 2016-05-02 | 2021-10-06 | F. Hoffmann-La Roche AG | The contorsbody - a single chain target binder |
| EP3504234A4 (en) * | 2016-09-29 | 2020-12-02 | Beijing Hanmi Pharmaceutical Co., Ltd. | CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES |
| SG10201913260VA (en) | 2016-11-18 | 2020-03-30 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
| BR112019020940A2 (pt) | 2017-04-11 | 2020-05-05 | Inhibrx, Inc. | construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| IL323061A (en) | 2018-04-11 | 2025-10-01 | Inhibrx Biosciences Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| FR3080621B1 (fr) * | 2018-04-26 | 2022-12-09 | Univ Limoges | Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde |
| CA3104390A1 (en) | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CA3114693A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
| CN113166263A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | Dll3单域抗体及其治疗性组合物 |
| WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| JP7453219B2 (ja) | 2018-10-11 | 2024-03-19 | インヒブリックス， インコーポレイテッド | Ｐｄ－１単一ドメイン抗体およびその治療用組成物 |
| IL319262A (en) | 2018-12-24 | 2025-04-01 | Sanofi Sa | Multispecific FAB pseudoproteins bind |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| CN115003695A (zh) * | 2019-12-26 | 2022-09-02 | 爱必乐生物公司 | 一种使用蛋白a亲和层析法纯化生物活性肽的方法 |
| KR20220148175A (ko) | 2020-01-29 | 2022-11-04 | 인히브릭스, 인크. | Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체 |
| CA3198102A1 (en) | 2020-10-07 | 2022-04-14 | Dren Bio, Inc. | Anti-dectin-1 antibodies and methods of use thereof |
| EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
| CN117642426A (zh) | 2021-06-16 | 2024-03-01 | 艾莱克特有限责任公司 | 双特异性抗MerTK和抗PDL1抗体及其使用方法 |
| JP2023092810A (ja) * | 2021-12-22 | 2023-07-04 | 国立大学法人東京農工大学 | 変異抗体、変異抗体の製造方法 |
| WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| EP4561614A1 (en) | 2022-07-29 | 2025-06-04 | Alector LLC | Cd98hc antigen-binding domains and uses therefor |
| EP4581059A2 (en) * | 2022-09-02 | 2025-07-09 | Zoetis Services LLC | Equine antibody mutants |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025087386A1 (zh) * | 2023-10-25 | 2025-05-01 | 正大天晴药业集团南京顺欣制药有限公司 | 抗her2抗体药物偶联物治疗乳腺癌的用途 |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| WO2025166077A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
| WO2025240670A2 (en) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE4419399C1 (de) | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE218143T1 (de) | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| US8142780B2 (en) * | 1998-08-20 | 2012-03-27 | Strox Biopharmaceuticals, Llc | Anti-bacterial antibodies |
| CN101213211A (zh) * | 2005-06-17 | 2008-07-02 | 惠氏公司 | 纯化含Fc区蛋白的方法 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| AU2009299792B2 (en) * | 2008-10-01 | 2015-07-16 | Amgen Research (Munich) Gmbh | Cross-species-specific PSMAxCD3 bispecific single chain antibody |
| EP3318573A1 (en) | 2008-12-23 | 2018-05-09 | F. Hoffmann-La Roche AG | Mmunoglobulin variants with altered binding to protein a |
| BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| PL2522724T3 (pl) * | 2009-12-25 | 2020-07-13 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania polipetydów do oczyszczania multimerów polipeptydowych |
| CA2796181C (en) * | 2010-04-20 | 2023-01-03 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| AU2012235758B2 (en) | 2011-03-25 | 2015-05-07 | IGI Therapeutics SA | Hetero-dimeric immunoglobulins |
| US9114516B2 (en) | 2011-07-21 | 2015-08-25 | Illinois Tool Works Inc. | Portable combustion gas-powered tools with combustion chamber lockout system |
| WO2013060867A2 (en) * | 2011-10-27 | 2013-05-02 | Genmab A/S | Production of heterodimeric proteins |
| AU2012372484A1 (en) | 2012-03-06 | 2014-08-21 | Foss Analytical Ab | Method, software and graphical user interface for forming a prediction model for chemometric analysis |
| EP3517548A1 (en) | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| EP3176185A1 (en) * | 2013-11-04 | 2017-06-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2013
- 2013-09-25 AU AU2013322710A patent/AU2013322710A1/en not_active Abandoned
- 2013-09-25 CA CA2886036A patent/CA2886036A1/en not_active Abandoned
- 2013-09-25 WO PCT/EP2013/069989 patent/WO2014049003A1/en not_active Ceased
- 2013-09-25 CN CN201380061419.1A patent/CN104968685A/zh active Pending
- 2013-09-25 US US14/431,207 patent/US20150239991A1/en not_active Abandoned
- 2013-09-25 EP EP13766540.2A patent/EP2900696A1/en not_active Ceased
- 2013-09-25 KR KR1020157010732A patent/KR20150076172A/ko not_active Ceased
- 2013-09-25 HK HK16103843.5A patent/HK1215950A1/zh unknown
- 2013-09-25 EP EP18177798.8A patent/EP3401337A1/en not_active Withdrawn
- 2013-09-25 IN IN139MUN2015 patent/IN2015MN00139A/en unknown
- 2013-09-25 CA CA3061557A patent/CA3061557A1/en active Pending
- 2013-09-25 JP JP2015532465A patent/JP2015529236A/ja active Pending
-
2015
- 2015-03-22 IL IL237872A patent/IL237872B/en active IP Right Grant
-
2018
- 2018-02-07 JP JP2018020450A patent/JP2018104444A/ja active Pending
- 2018-06-15 AU AU2018204314A patent/AU2018204314B2/en active Active
- 2018-11-30 JP JP2018224809A patent/JP6856610B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-14 US US16/275,821 patent/US20200010568A1/en not_active Abandoned
- 2019-09-09 IL IL269207A patent/IL269207B/en unknown
-
2020
- 2020-03-04 JP JP2020036853A patent/JP2020105203A/ja not_active Ceased
-
2022
- 2022-06-07 JP JP2022092045A patent/JP2022116326A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529236A5 (cg-RX-API-DMAC7.html) | ||
| JP6856610B2 (ja) | ヘテロ二量体免疫グロブリンの精製 | |
| KR102440737B1 (ko) | 이중특이적 항체에 대한 정제 플랫폼 | |
| JP6273219B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP2021004261A (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP2020506898A5 (cg-RX-API-DMAC7.html) | ||
| JP2020515518A5 (cg-RX-API-DMAC7.html) | ||
| JP2014158485A5 (cg-RX-API-DMAC7.html) | ||
| FI2560993T3 (fi) | Heterodimeeristä vasta-ainetta FC sisältävät proteiinit ja menetelmät niiden tuottamiseksi | |
| JP2011505810A5 (cg-RX-API-DMAC7.html) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| EP3026060A1 (en) | Humanized antibody or fragment thereof specific for CD45R0 | |
| JP2013520984A5 (cg-RX-API-DMAC7.html) | ||
| JP2016518333A5 (cg-RX-API-DMAC7.html) | ||
| CN114341184B (zh) | 抗FcRn抗体、其抗原结合片段及其医药用途 | |
| JP2025146842A (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| JP7653920B2 (ja) | 多段階クロマトグラフィープロセス中の望ましくない成分を除去する方法 | |
| AU2023207604A1 (en) | Methods for improving resolution of heterodimeric proteins from impurities using affinity chromatography | |
| EA049572B1 (ru) | Способы удаления нежелательных компонентов в многостадийных хроматографических процессах | |
| NZ737843B2 (en) | Tau-binding antibodies | |
| TH143301A (th) | นิวทรอลไลซ์ซิ่ง แอนติ-CCL-20 แอนติบอดี้ (NEUtralizing Anti-CCL-20 Antibodies) | |
| NZ774327B2 (en) | Therapeutic antibodies and their uses |